The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.
Understanding the diagnosis and treatment options empowered the patient, fostering a sense of control and preparedness. Maintaining a positive mental attitude and aligning with supportive healthcare ...
© 2026 Forbes Media LLC. All Rights Reserved.
Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...
The Food and Drug Administration’s approval of Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma offers an exciting treatment option, ...
Statin use in CLL/SLL patients treated with ibrutinib reduced cancer-related death risk by 61% and improved survival outcomes. The study found no significant increase in severe side effects with ...
© 2026 Forbes Media LLC. All Rights Reserved.
Wednesday 22 April 2026 1 SLL = 0.0044732 INR 0.0044666 0.0044753 SLL INR rate for 22/04/2026 Tuesday 21 April 2026 1 SLL = 0.0044647 INR 0.0044537 0.0044555 SLL INR rate for 21/04/2026 Monday 20 ...
Wednesday 22 April 2026 1 SLL = 0.00003532 GBP 0.00003534 0.00003523 SLL GBP rate for 22/04/2026 Tuesday 21 April 2026 1 SLL = 0.00003532 GBP 0.00003538 0.00003522 SLL GBP rate for 21/04/2026 Monday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results